Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.

ABSTRACT:

Purpose

Financial toxicity (FT) adversely influences patient quality of life and is a barrier to clinical trial enrollment. Early-phase clinical trials (EPCTs) recruit patients who may have high baseline FT and require additional visits and procedures, potentially increasing FT.

Methods

In this prospective survey study, we sought to assess FT at baseline and after 2 months among patients with advanced solid malignancies participating in EPCTs. Participants were age 18 years and older, were English-speaking, and were treated at the Yale Cancer Center (Yale) and the Tisch Cancer Institute at Mount Sinai (Mount Sinai). At the time of consent and 2 months later, patients completed a sociodemographic questionnaire as well as the 11-item validated Comprehensive Score for Financial

SUBMITTER: Blanter J 

PROVIDER: S-EPMC12508792 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature